Daily news and updates provided by the NEUROSURGERY® Editorial Office

Posts Tagged ‘acoustic neuroma

Ahead of Print: Cochlear Dose in the Radiosurgical Treatment of Vestibular Schwannoma

Background: Cochlear dose has been identified as a potentially modifiable contributor to hearing loss following stereotactic radiosurgery (SRS) for vestibular schwannoma (VS).

Objective: (1) to evaluate the association between CT-based volumetric cochlea dose and loss of serviceable hearing following SRS; 2) to assess intra- and interobserver reliability when determining modiolar point dose using MRI and CT; 3) and to discuss the clinical significance of the cochlea dose with regard to radiosurgical planning strategy.

Methods: Patients with serviceable pre-treatment hearing who underwent SRS for sporadic VS between using Gamma Knife Perfexion were studied. Univariate and multivariate associations with the primary outcome of time to non-serviceable hearing were evaluated.

Read the rest of this entry »

Free Editor Choice with CME: SRS for Neurofibromatosis 2-Associated Vestibular Schwannomas

Background: Management of neurofibromatosis type 2 (NF2)—associated vestibular schwannomas (VSs) remains controversial. Stereotactic radiosurgery (SRS) with conventional dosing is less effective for NF2-related VS compared with sporadic lesions.

Objective: To evaluate optimal SRS dose parameters for NF2-related VS and to report long-term outcomes.

Methods: A prospective database was reviewed and outcome measures, including radiographic progression, American Academy of Otolaryngology—Head and Neck Surgery hearing class, and facial nerve function, were analyzed. Progression-free survival was estimated with Kaplan-Meier methods. Associations between tumor progression and radiosurgical treatment parameters, tumor volume, and patient age were explored with the use of Cox proportional hazards regression.

Read the rest of this entry »

Written by NEUROSURGERY® Editorial Office

March 5, 2014 at 8:00 AM

Ahead of Print: Reduced-Dose Fractionated Stereotactic Radiotherapy for Acoustic Neuromas

Screen Shot 2013-07-16 at 10.46.38 AMBackground: Fractionated Stereotactic Radiotherapy (FSRT) is a non-invasive treatment for acoustic neuromas (AN). Initial reports from our institution demonstrated that reduction of treatment dose to 46.8 Gy resulted in improved preservation of functional hearing status.

Objective: We now report the tumor control (TC), symptomatic outcome, and hearing preservation rate (HP) in patients treated with reduced-dose FSRT.

Methods: We analyzed all patients with AN treated from 2002 to 2011. All patients received 46.8 Gy in 1.8 Gy fractions. Follow-up audiogram and MRI were performed in = one-year intervals. TC and HP were calculated by the Kaplan-Meier method. Analysis of HP, defined as Gardner-Robertson value = 2, was determined by audiometric data. Non-hearing related symptoms were defined by Common Terminology Criteria for Adverse Events version 4.

Read the rest of this entry »

Written by NEUROSURGERY® Editorial Office

July 18, 2013 at 8:00 AM

Ahead of Print: JNK Inhibition Enhances Schwannoma Radiosensitivity

Screen Shot 2013-06-11 at 2.40.11 PMBackground: Radiosurgery is increasingly used to treat vestibular schwannomas (VSs). Increasing the sensitivity of VS cells to irradiation (IR) could allow for lower and/or more effective doses of IR, improving safety and efficacy. Persistent c-Jun N-terminal kinase (JNK) activity in VS cells reduces cell death by suppressing accumulation of reactive oxygen species (ROS), raising the possibility that JNK activity protects against IR-induced VS cell death, which is mediated by ROS.

Objective: To determine the extent to which JNK signaling contributes to VS cell radiosensitivity.

Methods: Primary human VS cultures, derived from acutely resected tumors, received single doses (5-40 Gy) of [gamma]-irradiation. Histone 2AX phosphorylation, a marker of IR-induced DNA damage, was assayed by western blot and immunostaining. ROS levels were quantified by measuring 2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) fluorescence. Cell apoptosis was determined by terminal deoxynucleotidyl transferase dUTP nick end labeling.

Read the rest of this entry »

Written by NEUROSURGERY® Editorial Office

July 1, 2013 at 2:00 PM

Free Editor Choice: Contemporary Surgical Management of Vestibular Schwannomas

Background: Despite advanced microsurgical techniques, more refined instrumentation, and expert team management, there is still a significant incidence of complications in vestibular schwannoma surgery.

Objective: To analyze complications from the microsurgical treatment of vestibular schwannoma by an expert surgical team and to propose strategies for minimizing such complications.

Methods: Surgical outcomes and complications were evaluated in a consecutive series of 410 unilateral vestibular schwannomas treated from 2000 to 2009. Clinical status and complications were assessed postoperatively (within 7 days) and at the time of follow-up (range, 1-116 months; mean, 32.7 months).

Read the rest of this entry »

Written by NEUROSURGERY® Editorial Office

May 28, 2013 at 2:00 PM


Get every new post delivered to your Inbox.

Join 12,998 other followers